Roche says Lunsumio plus lenalidomide improves PFS in CELESTIMO
Roche announced phase III CELESTIMO results for Lunsumio (mosunetuzumab) plus lenalidomide versus MabThera/Rituxan (rituximab) plus lenalidomide in relapsed or refractory follicular lymphoma.
Roche said on 17 September 2026 that the phase III CELESTIMO study of Lunsumio® (mosunetuzumab) with lenalidomide met its primary endpoint versus MabThera®/Rituxan® (rituximab) plus lenalidomide in people with relapsed or refractory (R/R) follicular lymph…